~~<i id='9B9E8B63AA'><strike id='9B9E8B63AA'><tt id='9B9E8B63AA'><pre id='9B9E8B63AA'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：knowledge 2025-10-02 04:40:16 Page View：7832

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： RaDonda Vaught links Vanderbilt hospital issues to patient death
Next article： The high cost of giving birth even with insurance

comprehensive

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Change Healthcare outage fallout shows need for new oversight

AdobeIntheearlydaysafteritwashitbyacyberattackonFeb.21,ChangeHealthcare,oneofthecountry’slargestclai

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

FILE-HandgunsaredisplayedatagunshoponJune,23,2022,inHonolulu.ThreeHawaiiresidentschallengingthestate